CD19 and acute lymphoblastic leukemia: Moreover, CRISPR/Cas9 technology was used to target a CD19‐specific CAR to TCRα subunit constant (TRAC) sites to achieve the even expression of CAR in human peripheral blood T cells and to enhance the CAR‐T cell function examined in an acute lymphoblastic leukemia mouse model [142, 143].